| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Sunday, August 28, 2022 5:25:21 PM
You’ve changed arguments. All new ones.
On the regulatory front, I think the evidence again shows you’re wrong. I can’t think of another cancer treatment that a regulator is allowing to be sold at full cost before it is approved. Can you?
The other approvals in the UK are evidence to the contrary. The change in policies by the FDA on external control arms and explicitly discussing neurological cancers in the instances where it is discussed, specifically in that most recent journal article authored by FDA officials including Dr. Pazdur, as I have always said, almost suggests that this policy was custom designed for this trial. It wasn’t, it is a part of the 21st a century Cures Act and a Cancer moonshot efforts, that Dr. Pazdur is leading directly, but their references to neurological cancers I think shows that they are covert clearly aware of this trial and the questions about their own past methodology that it raised. I see no evidence that anything is wrong with the regulators, just the usual slowness. No, the trial is completed for purposes of approval, and I do not see this delayed to 2024. I guess there is worry about the stock rising, but when people snort a stock, that is a risk.
Dr. Liau certainly is promoting both the specific vaccine, with her presentation of the results in Europe and her traveling across country to promote the trial, use of external control arm and also her talk about the use of the adjuvants and the combination in virtually all of her recent talks. She has led a set of discussions across the country and internationally, over many months, and many of those lectures are available on YouTube, though not all.
Again, why falsely color the facts and narrative to make points that are not consistent with the current reality?
Interesting new arguments but false.
On the regulatory front, I think the evidence again shows you’re wrong. I can’t think of another cancer treatment that a regulator is allowing to be sold at full cost before it is approved. Can you?
The other approvals in the UK are evidence to the contrary. The change in policies by the FDA on external control arms and explicitly discussing neurological cancers in the instances where it is discussed, specifically in that most recent journal article authored by FDA officials including Dr. Pazdur, as I have always said, almost suggests that this policy was custom designed for this trial. It wasn’t, it is a part of the 21st a century Cures Act and a Cancer moonshot efforts, that Dr. Pazdur is leading directly, but their references to neurological cancers I think shows that they are covert clearly aware of this trial and the questions about their own past methodology that it raised. I see no evidence that anything is wrong with the regulators, just the usual slowness. No, the trial is completed for purposes of approval, and I do not see this delayed to 2024. I guess there is worry about the stock rising, but when people snort a stock, that is a risk.
Dr. Liau certainly is promoting both the specific vaccine, with her presentation of the results in Europe and her traveling across country to promote the trial, use of external control arm and also her talk about the use of the adjuvants and the combination in virtually all of her recent talks. She has led a set of discussions across the country and internationally, over many months, and many of those lectures are available on YouTube, though not all.
Again, why falsely color the facts and narrative to make points that are not consistent with the current reality?
Interesting new arguments but false.
I own NWBO. My posts on iHub are always posted expressly as just my humble opinion (IMHO) and none are advice, just my opinion. I am NOT a financial advisor, and it is assumed that everyone is responsible for their own due diligence.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
